Current Headlines

  1. New Partnership With Parkinson's Research Foundation To Accelerate Parkinson's Drug Discovery 7/17/2025

    WEHI has formed a partnership with the Parkinson’s Research Foundation with one clear goal: to intensify the search for drug treatments to stop Parkinson’s.

  2. Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development 7/16/2025

    Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities.

  3. C-Path's Translational Therapeutics Accelerator Announces $200,000 Grant For Drug Development Project In Inflammatory Bowel Disease 7/16/2025

    Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $200,000 grant to Carlos Subauste, MD, an internist and infectious disease specialist at University Hospitals Cleveland Medical Center and professor at Case Western Reserve University, to advance a promising new therapy for inflammatory bowel disease (IBD).

  4. SandboxAQ And iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery For Glioblastoma 7/16/2025

    SandboxAQ and iOncologi today announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults.

  5. Blocking A Little-Known Protein May Offer New Hope For Devastating Lung Disease 7/15/2025

    Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease.

  6. Corcept Submits New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer 7/14/2025

    Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer.

  7. Integrated Biosciences Unveils First-Of-Its-Kind Optogenetic Screening Platform For Drug Discovery 7/14/2025

    Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, today announced the publication of a landmark study in Cell, introducing its first-of-a-kind optogenetic screening platform.

  8. Divamics' AI And Molecular Dynamics Platform Powers Breakthroughs In Metabolic Disease Drug Discovery For Partners 7/14/2025

    Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform.

  9. TandemAI And Perpetual Medicines Announce Strategic Merger To Expand Physics And AI-Based Drug Discovery Capabilities 7/10/2025

    TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a computational design-synthesis platform for peptide drug discovery today announced the companies have merged.

  10. U.S. FDA Accepts New Drug Application For Merck's Doravirine/Islatravir, An Investigational, Once-Daily, Oral, Two-Drug Regimen For Treatment Of Adults With Virologically Suppressed HIV-1 Infection 7/10/2025

    Merck, known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy.